MADISON, Wis.--(BUSINESS WIRE)--BioTechnique, LLC (“BioTechnique”) announced today the launch of the second phase of manufacturing in partnership with a major, international not-for-profit organization. Under this partnership, BioTechnique will manufacture a commercially-available vaccine product in a new, shelf-stable dosage form. In the first phase of manufacturing, BioTechnique produced the same vaccine product in late 2015. The vaccine met all analytical and release testing specifications and entered the clinic in early 2016.
“We are very pleased to support a major non-profit trust in bringing their novel dosage form to market,” said John Clapham, BioTechnique CEO. “With the continuation of this live attenuated virus manufacturing partnership, we have broadened our ability meet demand from our customers who need a reliable contract manufacturing partner.”
“The successful completion of our first project marked our official transition into an operational CMO. This feat could not have been accomplished without a team effort from the BioTechnique organization. Our previous accomplishments indicate we are well-situated to continue this momentum into phase II of this partnership,” stated Raphi Hanessian, General Manager, BioTechnique.
BioTechnique™ is a specialty drug aseptic fill-finish contract manufacturing organization (CMO) with significant expertise in cytotoxic and highly potent sterile injectable manufacturing located in Madison, Wisconsin. BioTechnique’s mission is to manufacture tomorrow’s revolutionary cancer therapies to the highest international standards. BioTechnique provides compounding, fill-finish, and optional lyophilization services for a variety of sterile injectables in clinical and commercial batch sizes. From IND applications through commercial scale production, BioTechnique works with each client to create a custom, comprehensive pharmaceutical development strategy that ensures the highest quality sterile injectable product is delivered on time and on budget.
Our parent company, PSC Biotech™, is a global life sciences consultancy that was founded in 1996 with the vision of providing life science companies mission-critical professional services. Over the last twenty years, PSC has grown and diversified to become a one-stop life science service and solution provider that offers engineering consulting, quality management software, contract pharmaceutical manufacturing, and strategic and investment advisory services worldwide.